Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Summary
Between 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess. In approximately 50% of these patients, the tumoral source of ACTH cannot be found initially despite very detailed and extensive imaging, including studies such as computed tomography, magnetic resonance imaging, and octreotide scan (Octreoscan) using the standard dose of indium- 111 pentetreotide (\[111In-DTPA-D-Phe\]-pentetreotide). The sensitivity and specificity of structurally based imaging studies depends on anatomic alterations and the size of the tumor. In contrast, positron emission tomography (PET) and somatostatin ligand imaging detect pathologic tissue based on physiologic and biochemical processes within the abnormal tissue. This protocol tests the ability of \[18F\]-L-3,4-dihydroxyphenylalanine (18F-DOPA) PET, and the somatostatin imaging analogue, 68Ga-DOTATATE-PET, to localize the source of ectopic ACTH production.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2014-02-12
Completion Date
2030-12-31
Last Updated
2026-04-02
Healthy Volunteers
No
Conditions
Interventions
DOTATATE PET-CT
68Ga-DOTATATE PET/CT
F-DOPA PET CT
68Ga-DOTATATE PET/CT
CT scan
routine CT scan
Routine MRI scan
routine 1.5 or 3T MRI scan
Gated MRI scan
Cardiac gated MRI scan
68Ga-DOTATATE
68Ga-DOTATATE radioligand
18F-DOPA
18F-DOPA radioligand
Locations (1)
National Institutes of Health Clinical Center
Bethesda, Maryland, United States